Vasoactive intestinal peptide (VIP) has been found to act as a potent anti-inflammatory factor in experimental arthritis through regulating the production of both anti- and proinflammatory mediators and promoting Th2-type responses [21]. This evidence concerns the gene VIP and arthritic joint disease.